Audited Financial Results for the quarter and year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Samrat Pharmachem reported a net loss of Rs 331.20 lakhs for FY2026 compared to a net profit of Rs 711.22 lakhs in FY2025, a dramatic turnaround. Revenue grew marginally by 1.35% to Rs 28,972.12 lakhs, but cost of raw materials surged significantly to Rs 28,966.68 lakhs (up from Rs 26,927.10 lakhs), compressing margins. Finance costs also increased to Rs 95.53 lakhs from Rs 67.41 lakhs. The company posted a loss before tax of Rs 298.10 lakhs versus a profit of Rs 988.61 lakhs in the prior year. Cash flow from operations remained positive at Rs 887.99 lakhs. Auditors issued an unmodified opinion confirming the financial statements are fairly stated.
The company swung from profit to significant loss due to sharply higher material costs and finance expenses. While auditors gave a clean opinion and operating cash flow stayed positive, the loss-making position is a serious red flag for investors. Shareholders should monitor if cost pressures persist in Q1 FY2027.